LIVIVO - Search results -

Search results

Result 1 - 10 of total 42

Search options

Article: Preparing for uncertainty during public health emergencies: What Canadian health leaders can do now to optimize future emergency response.

Tam, Theresa W S

2020 Volume 33, Issue 4, Page(s) 174–177

Abstract: It is clear that the risk for epidemics with high health and socio-economic impacts remains but there will be many unknowns at the start of future responses to these events. This article highlights principles and practices to assist health leaders in ... ...

Abstract	It is clear that the risk for epidemics with high health and socio-economic impacts remains but there will be many unknowns at the start of future responses to these events. This article highlights principles and practices to assist health leaders in preparing for uncertainty, including integrating scalability to ensure response activities can be more easily adapted to suit evolving needs; assessing risk and capabilities to inform planning for appropriate response measures; and considering overall flexibility and adaptability of plans, systems, and resources. Ultimately, being prepared for "Disease X" is about applying the approaches that we have learned from previous events, using evidence-based practices to develop and strengthen foundational capacities, so that we are able to respond to the unanticipated in proportionate and appropriate ways.
MeSH term(s)	Canada ; Emergencies ; Health Planning ; Humans ; Influenza A Virus, H1N1 Subtype ; Policy Making ; Public Health ; Risk Assessment ; Uncertainty
Keywords	covid19
Language	English
Publishing date	2020-03-31
Publishing country	United States
Document type	Journal Article
ZDB-ID	2140831-2
ISSN	2352-3883 ; 0840-4704
ISSN (online)	2352-3883
ISSN	0840-4704
DOI	10.1177/0840470420917172
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5895: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?

Tam, Theresa W S

Paediatrics & child health

2018 Volume 23, Issue 1, Page(s) 31–34

Abstract: Canada and the USA differ in their recommendations for the use of live attenuated influenza vaccine (LAIV). The Canadian National Advisory Committee on Immunization (NACI) continues to recommend LAIV as one of the influenza vaccines available for use in ... ...

Abstract	Canada and the USA differ in their recommendations for the use of live attenuated influenza vaccine (LAIV). The Canadian National Advisory Committee on Immunization (NACI) continues to recommend LAIV as one of the influenza vaccines available for use in children 2 to 17 years of age. The US Advisory Committee on Immunization Practices (ACIP) made an interim recommendation against the use of LAIV for the 2016 to 2017 influenza season in response to low LAIV effectiveness observed in the USA during the 2013 to 2014 to 2015 to 2016 seasons. The recommendation has been continued for the 2017 to 2018 season. In response, NACI undertook a review of available LAIV effectiveness data in children and adolescents from Canada, the USA and a number of European countries. This commentary by Canada's Chief Public Health Officer summarizes the findings of that review and provides the rationale for Canada's current continued recommendation for LAIV use.
Language	English
Publishing date	2018-01-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2106767-3
ISSN	1918-1485 ; 1205-7088
ISSN (online)	1918-1485
ISSN	1205-7088
DOI	10.1093/pch/pxx195
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5774: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study).

Wedner, H James / Fujisawa, Takao / Guilbert, Theresa W / Ikeda, Masanori / Mehta, Vinay / Tam, Jonathan S / Lukka, Pradeep B / Asimus, Sara / Durżyński, Tomasz / Johnston, James / White, Wendy I / Shah, Mihir / Werkström, Viktoria / Jison, Maria L

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

2024 Volume 35, Issue 3, Page(s) e14092

Abstract: Background: Benralizumab is an anti-interleukin-5 receptor α monoclonal antibody approved as an add-on maintenance treatment for patients with uncontrolled severe asthma. Prior Phase 3 studies have evaluated benralizumab in patients aged ≥12 years with ... ...

Abstract	Background: Benralizumab is an anti-interleukin-5 receptor α monoclonal antibody approved as an add-on maintenance treatment for patients with uncontrolled severe asthma. Prior Phase 3 studies have evaluated benralizumab in patients aged ≥12 years with severe uncontrolled asthma. The TATE study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), and safety of benralizumab treatment in children. Methods: TATE was an open-label, Phase 3 study of benralizumab in children aged 6-11 years from the United States and Japan (plus participants aged 12-14 years from Japan) with severe eosinophilic asthma. Participants received benralizumab 10/30 mg according to weight (<35/≥35 kg). Primary endpoints included maximum serum concentration (C Results: Twenty-eight children aged 6-11 years were included, with an additional two participants from Japan aged 12-14 years also included in the popPK analysis. Mean C Conclusion: PK, PD, and safety data support long-term benralizumab in children with severe eosinophilic asthma, and were similar to findings in adolescents and adults. Trial registration: ClinicalTrials.gov-ID: NCT04305405.
MeSH term(s)	Adult ; Child ; Adolescent ; Humans ; Anti-Asthmatic Agents/adverse effects ; Disease Progression ; Double-Blind Method ; Asthma/drug therapy ; Asthma/chemically induced ; Eosinophils ; Antibodies, Monoclonal, Humanized
Chemical Substances	Anti-Asthmatic Agents ; benralizumab (71492GE1FX) ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2024-03-16
Publishing country	England
Document type	Journal Article
ZDB-ID	1057059-7
ISSN	1399-3038 ; 0905-6157 ; 0906-5784
ISSN (online)	1399-3038
ISSN	0905-6157 ; 0906-5784
DOI	10.1111/pai.14092
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3096: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mesothelioma: Pleural, Version 1.2024.

Stevenson, James / Ettinger, David S / Wood, Douglas E / Aisner, Dara L / Akerley, Wallace / Bauman, Jessica R / Bharat, Ankit / Bruno, Debora S / Chang, Joe Y / Chirieac, Lucian R / DeCamp, Malcolm / Desai, Aakash / Dilling, Thomas J / Dowell, Jonathan / Durm, Gregory A / Garassino, Marina C / Gettinger, Scott / Grotz, Travis E / Gubens, Matthew A /

Lackner, Rudy P / Lanuti, Michael / Lin, Jules / Loo, Billy W / Lovly, Christine M / Maldonado, Fabien / Massarelli, Erminia / Morgensztern, Daniel / Mullikin, Trey C / Ng, Thomas / Otterson, Gregory A / Owen, Dawn / Patel, Sandip P / Patil, Tejas / Polanco, Patricio M / Riely, Gregory J / Riess, Jonathan / Shapiro, Theresa A / Singh, Aditi P / Tam, Alda / Tanvetyanon, Tawee / Yanagawa, Jane / Yang, Stephen C / Yau, Edwin / Gregory, Kristina / Hang, Lisa

Journal of the National Comprehensive Cancer Network : JNCCN

2024 Volume 22, Issue 2, Page(s) 72–81

Abstract: Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents ... ...

Abstract	Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.
MeSH term(s)	Humans ; Pleura ; Mesothelioma/diagnosis ; Mesothelioma/therapy ; Mesothelioma, Malignant ; Pleural Neoplasms/diagnosis ; Pleural Neoplasms/therapy
Language	English
Publishing date	2024-03-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2250759-0
ISSN	1540-1413 ; 1540-1405
ISSN (online)	1540-1413
ISSN	1540-1405
DOI	10.6004/jnccn.2024.0014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Thresholds in PROMIS Scores Anchored to Subsequent Unscheduled Health Service Use Among People Diagnosed With Cancer.

Sikorskii, Alla / Tam, Samantha / Given, Barbara / Given, Charles W / Adjei Boakye, Eric / Zatirka, Theresa / Nair, Mrudula / Su, Wan-Ting K / Jogunoori, Smitha / Watson, Peter / Movsas, Benjamin / Chang, Steven

JCO oncology practice

2024 , Page(s) OP2300356

Abstract: Purpose: To establish thresholds in the Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference, physical function, fatigue, and depression scores on the basis of their association with subsequent use of the emergency ... ...

Abstract	Purpose: To establish thresholds in the Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference, physical function, fatigue, and depression scores on the basis of their association with subsequent use of the emergency department (ED) or urgent care by people diagnosed with cancer. Methods: Retrospective data from 952 people seen at Henry Ford Cancer and insured through the Health Alliance Plan were analyzed using generalized linear mixed-effects models. The log odds of ED or urgent care use during 14 or 30 days after each patient-reported outcome (PRO) assessment were related to PRO scores, while adjusting for comorbidity, sociodemographic, and tumor characteristics. Results: Pain interference and physical function were associated with subsequent ED or urgent care visits, but fatigue and depression were not, and the results for 14- and 30-day visits were similar. Thresholds anchored in the likelihood of these visits differed according to cancer stage. For people with advanced cancer, a pain interference score of 60 or higher (odds ratio [OR] 3.75, [95% CI, 1.53 to 7.87]) and a physical function score lower than 40 (OR 2.94, [95% CI, 1.22 to 7.06]) produced the largest ORs with narrowest CIs for 30-day visits. For people with nonadvanced cancer, the thresholds of 65 for pain interference (OR 2.64, [95% CI, 1.40 to 5.01]) and 35 for physical function (OR 1.87, [95% CI, 1.01 to 3.45]) produced largest ORs with narrowest CIs for 30-day visits. Conclusion: These anchor-based thresholds in PROMIS scores can inform clinicians' actions with the goal of preventing ED or urgent care visits.
Language	English
Publishing date	2024-04-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	3028198-2
ISSN	2688-1535 ; 2688-1527
ISSN (online)	2688-1535
ISSN	2688-1527
DOI	10.1200/OP.23.00356
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Knowledge is power: regarding SMFM Consult Series #64: Systemic lupus erythematosus in pregnancy.

Cuneo, Bettina F / Buyon, Jill P / Sammaritano, Lisa / Jaeggi, Edgar / Arya, Bhawna / Behrendt, Nicholas / Carvalho, Julene / Cohen, Jennifer / Cumbermack, Kristopher / DeVore, Greggory / Doan, Tam / Donofrio, Mary T / Freud, Lindsay / Galan, Henry L / Gropler, Melanie R F / Haxel, Caitlin / Hornberger, Lisa K / Howley, Lisa W / Izmirly, Peter /

Killen, Stacy S / Kaplinski, Michelle / Krishnan, Anita / Lavasseur, Stephanie / Lindblade, Christopher / Matta, Jyothi / Makhoul, Majd / Miller, Jena / Morris, Shaine / Paul, Erin / Perrone, Erin / Phoon, Colin / Pinto, Nelangi / Rychik, Jack / Satou, Gary / Saxena, Amit / Sklansky, Mark / Stranic, James / Strasburger, Janette F / Srivastava, Shubhika / Srinivasan, Sharda / Tacy, Theresa / Tworetzky, Wayne / Uzun, Orhan / Yagel, Simcha / Zaretsky, Michael V / Moon-Grady, Anita J

American journal of obstetrics and gynecology

2023 Volume 229, Issue 4, Page(s) 361–363

MeSH term(s)	Pregnancy ; Female ; Humans ; Lupus Erythematosus, Systemic/diagnosis ; Pregnancy Complications/diagnosis ; Pregnancy Complications/therapy
Language	English
Publishing date	2023-07-01
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	80016-8
ISSN	1097-6868 ; 0002-9378
ISSN (online)	1097-6868
ISSN	0002-9378
DOI	10.1016/j.ajog.2023.06.040
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Um I Zs.152: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Ettinger, David S / Wood, Douglas E / Stevenson, James / Aisner, Dara L / Akerley, Wallace / Bauman, Jessica R / Bharat, Ankit / Bruno, Debora S / Chang, Joe Y / Chirieac, Lucian R / DeCamp, Malcolm / Dilling, Thomas J / Dowell, Jonathan / Durm, Gregory A / Gettinger, Scott / Grotz, Travis E / Gubens, Matthew A / Hegde, Aparna / Lackner, Rudy P /

Journal of the National Comprehensive Cancer Network : JNCCN

2023 Volume 21, Issue 9, Page(s) 961–979

Abstract: Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM ... ...

Abstract	Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose. The term "malignant" is no longer used to classify mesotheliomas, because all mesotheliomas are now defined as malignant.
MeSH term(s)	Humans ; Medical Oncology ; Mesothelioma/diagnosis ; Mesothelioma/therapy ; Mesothelioma, Malignant ; Peritoneum
Language	English
Publishing date	2023-08-26
Publishing country	United States
Document type	Journal Article ; Practice Guideline
ZDB-ID	2250759-0
ISSN	1540-1413 ; 1540-1405
ISSN (online)	1540-1413
ISSN	1540-1405
DOI	10.6004/jnccn.2023.0045
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Ettinger, David S / Wood, Douglas E / Aisner, Dara L / Akerley, Wallace / Bauman, Jessica R / Bharat, Ankit / Bruno, Debora S / Chang, Joe Y / Chirieac, Lucian R / DeCamp, Malcolm / Dilling, Thomas J / Dowell, Jonathan / Durm, Gregory A / Gettinger, Scott / Grotz, Travis E / Gubens, Matthew A / Hegde, Aparna / Lackner, Rudy P / Lanuti, Michael /

Journal of the National Comprehensive Cancer Network : JNCCN

2023 Volume 21, Issue 4, Page(s) 340–350

Abstract: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options ... ...

Abstract	The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/diagnosis ; Lung Neoplasms/therapy ; Neoadjuvant Therapy
Language	English
Publishing date	2023-04-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	2250759-0
ISSN	1540-1413 ; 1540-1405
ISSN (online)	1540-1413
ISSN	1540-1405
DOI	10.6004/jnccn.2023.0020
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.

Sugita, Mayumi / Wilkes, David C / Bareja, Rohan / Eng, Kenneth W / Nataraj, Sarah / Jimenez-Flores, Reyna A / Yan, LunBiao / De Leon, Jeanne Pauline / Croyle, Jaclyn A / Kaner, Justin / Merugu, Swathi / Sharma, Sahil / MacDonald, Theresa Y / Noorzad, Zohal / Panchal, Palak / Pancirer, Danielle / Cheng, Shuhua / Xiang, Jenny Z / Olson, Luke /

Van Besien, Koen / Rickman, David S / Mathew, Susan / Tam, Wayne / Rubin, Mark A / Beltran, Himisha / Sboner, Andrea / Hassane, Duane C / Chiosis, Gabriela / Elemento, Olivier / Roboz, Gail J / Mosquera, Juan Miguel / Guzman, Monica L

NPJ precision oncology

2021 Volume 5, Issue 1, Page(s) 44

Abstract: The epichaperome is a new cancer target composed of hyperconnected networks of chaperome members that facilitate cell survival. Cancers with an altered chaperone configuration may be susceptible to epichaperome inhibitors. We developed a flow cytometry- ... ...

Abstract	The epichaperome is a new cancer target composed of hyperconnected networks of chaperome members that facilitate cell survival. Cancers with an altered chaperone configuration may be susceptible to epichaperome inhibitors. We developed a flow cytometry-based assay for evaluation and monitoring of epichaperome abundance at the single cell level, with the goal of prospectively identifying patients likely to respond to epichaperome inhibitors, to measure target engagement, and dependency during treatment. As proof of principle, we describe a patient with an unclassified myeloproliferative neoplasm harboring a novel PML-SYK fusion, who progressed to acute myeloid leukemia despite chemotherapy and allogeneic stem cell transplant. The leukemia was identified as having high epichaperome abundance. We obtained compassionate access to an investigational epichaperome inhibitor, PU-H71. After 16 doses, the patient achieved durable complete remission. These encouraging results suggest that further investigation of epichaperome inhibitors in patients with abundant baseline epichaperome levels is warranted.
Language	English
Publishing date	2021-05-26
Publishing country	England
Document type	Journal Article
ISSN	2397-768X
ISSN	2397-768X
DOI	10.1038/s41698-021-00183-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals.

Schanzer, Dena L / Langley, Joanne M / Tam, Theresa W S

Influenza and other respiratory viruses

2009 Volume 2, Issue 1, Page(s) 1–8

Abstract: Objective: We sought to estimate age-specific hospitalization rates attributed to influenza and other virus for adults.: Methods: Admissions from Canada's national hospitalization database (Canadian Institute of Health Information), from 1994/95 to ... ...

Abstract	Objective: We sought to estimate age-specific hospitalization rates attributed to influenza and other virus for adults. Methods: Admissions from Canada's national hospitalization database (Canadian Institute of Health Information), from 1994/95 to 1999/2000, were modeled as a function of proxy variables for influenza, respiratory syncytial virus (RSV) and other viral activity, seasonality and trend using a Poisson regression model and stratified by age group. Results: The average annual influenza-attributed hospitalization rate for all adults, 20 years of age or older, over the study period, which included three severe seasons, was an estimated 65/100,000 population (95% CI 63-67). Among persons aged 65 and over, 270-340 admissions per 100,000 population per year were attributed to influenza, while 30-110, 60-90 and 130-350 per 100,000 were attributed to RSV, parainfluenza (PIV) and other respiratory viruses, respectively. Although marked season-to-season variation in age-specific hospitalization rates attributable to influenza was observed in persons 50 years of age and older, increasing risk with age was preserved at all time periods. Conclusions: Influenza, RSV, PIV and other respiratory viruses were all associated with morbidity requiring hospitalization, while influenza was responsible for peak respiratory admissions. The burden of health care utilization associated with respiratory viruses is appreciable beginning in the sixth decade and increases significantly with age.
MeSH term(s)	Adult ; Age Factors ; Aged ; Aged, 80 and over ; Canada/epidemiology ; Female ; Hospitalization/trends ; Humans ; Incidence ; Male ; Middle Aged ; Respiratory Tract Infections/epidemiology ; Respiratory Tract Infections/virology ; Risk Factors ; Seasons ; Viruses/classification ; Viruses/isolation & purification ; Young Adult
Language	English
Publishing date	2009-03-30
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2274538-5
ISSN	1750-2659 ; 1750-2640
ISSN (online)	1750-2659
ISSN	1750-2640
DOI	10.1111/j.1750-2659.2008.00035.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6568: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito